ASO作者反思：里程碑系列——可切除胰腺癌的新辅助治疗 - Suppr | 超能文献

ASO Author Reflections: The Landmark Series-Neoadjuvant Therapy for Resectable Pancreatic Cancer.

作者信息

Dekker Esther N, Tzeng Ching-Wei D

机构信息

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

出版信息

Ann Surg Oncol. 2025 Sep;32(9):6571-6572. doi: 10.1245/s10434-025-17835-3. Epub 2025 Jul 10.

DOI:10.1245/s10434-025-17835-3

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

ASO Author Reflections: The Landmark Series-Neoadjuvant Therapy for Resectable Pancreatic Cancer.ASO作者反思：里程碑系列——可切除胰腺癌的新辅助治疗

Ann Surg Oncol. 2025 Sep;32(9):6571-6572. doi: 10.1245/s10434-025-17835-3. Epub 2025 Jul 10.

2

ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicator for Neoadjuvant Therapy.ASO作者反思：优化可切除胰腺癌的治疗：CA19-9>500 U/mL作为新辅助治疗的生物学指标

Ann Surg Oncol. 2025 May 21. doi: 10.1245/s10434-025-17458-8.

3

ASO Author Reflections: Novel Evidence on Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer with Arterial Involvement.ASO作者反思：关于新辅助化疗治疗伴有动脉侵犯的可切除边缘胰腺癌的新证据

Ann Surg Oncol. 2023 Jan;30(1):203-204. doi: 10.1245/s10434-022-12584-z. Epub 2022 Sep 21.

4

ASO Author Reflections: Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer: Is Combined Radiotherapy Necessary?ASO作者反思：可切除边缘胰腺癌的新辅助治疗：联合放疗是否必要？

Ann Surg Oncol. 2019 Jun;26(6):1637-1638. doi: 10.1245/s10434-019-07245-7. Epub 2019 Feb 19.

5

ASO Author Reflections: Neoadjuvant Treatment of Resectable and Borderline-Resectable Pancreatic Head Adenocarcinoma: Is FOLFIRINOX Better than Gem/Nab-Paclitaxel?ASO作者反思：可切除及边界可切除胰头腺癌的新辅助治疗：FOLFIRINOX方案是否优于吉西他滨/纳米白蛋白结合型紫杉醇？

Ann Surg Oncol. 2018 Dec;25(Suppl 3):808-809. doi: 10.1245/s10434-018-6833-7. Epub 2018 Oct 8.

6

ASO Author Reflections: Pancreatic Cancer Having Tumor Contact with an Aberrant Right Hepatic Artery Should be Regarded as Technically Resectable but Oncologically Borderline-Resectable.ASO作者反思：与异常右肝动脉有肿瘤接触的胰腺癌应被视为技术上可切除但肿瘤学上接近可切除。

Ann Surg Oncol. 2022 Aug;29(8):4989-4990. doi: 10.1245/s10434-022-11639-5. Epub 2022 Apr 21.

7

ASO Author Reflections: Neoadjuvant Chemoradiotherapy for Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancreatectomy Changes Body Composition Influencing Long-term Outcomes.ASO作者反思：接受胰十二指肠切除术的可切除和边界可切除胰腺导管腺癌患者的新辅助放化疗改变身体成分，影响长期预后。

Ann Surg Oncol. 2023 Apr;30(4):2469-2470. doi: 10.1245/s10434-022-13024-8. Epub 2022 Dec 25.

8

ASO Author Reflections: The Impact of Adjuvant Therapy in the Era of Neoadjuvant Strategies for Pancreatic Cancer.ASO作者反思：辅助治疗在胰腺癌新辅助治疗策略时代的影响

Ann Surg Oncol. 2025 Jul 5. doi: 10.1245/s10434-025-17788-7.

9

ASO Author Reflections: Indication Criteria for Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma.ASO作者反思：可切除胰腺导管腺癌新辅助治疗的适应证标准

Ann Surg Oncol. 2025 Apr;32(4):2866-2867. doi: 10.1245/s10434-025-16980-z. Epub 2025 Feb 9.

10

ASO Author Reflections: Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer on Surgical Outcomes.ASO作者反思：吉西他滨联合白蛋白结合型紫杉醇新辅助化疗对可切除边缘性胰腺癌手术结局的影响

Ann Surg Oncol. 2019 Dec;26(Suppl 3):739-740. doi: 10.1245/s10434-019-07857-z. Epub 2019 Sep 19.

本文引用的文献

1

Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial.可切除胰腺腺癌围手术期化疗的疗效：一项 2 期随机临床试验。

JAMA Oncol. 2021 Mar 1;7(3):421-427. doi: 10.1001/jamaoncol.2020.7328.